Major Funding Secured for Innovative Oral Therapy Development

CellCentric Ltd. has completed a USD 220 million (approximately 220 million USD) Series D financing round, led by venture capital firm Venrock. The funds will be used to accelerate the pivotal trial and late-stage development of 'inobrodib (CCS1477),' an oral p300/CBP protein dual inhibitor being developed as a next-generation treatment for multiple myeloma. This investment reflects the high expectations within the investment community for convenient oral drugs in the multiple myeloma market, which has traditionally been dominated by cell therapies and intravenous injections.

Addressing Treatment Limitations in the Multiple Myeloma Market and the Clinical Significance of Oral Therapies

The multiple myeloma treatment market is currently valued at approximately USD 24 billion to 29 billion in 2025 and is projected to grow rapidly to over USD 35 billion by 2030. However, patients who progress to relapsed/refractory multiple myeloma (RRMM) after failing initial and second-line treatments face a significant decline in survival rates. Inobrodib possesses a novel p300/CBP target mechanism that blocks the expression of cancer-causing genes. It is expected to improve patients' quality of life and reduce healthcare costs by providing a convenient oral medication that can be easily administered at home, without requiring hospital visits.

Progress in Pivotal Clinical Trials and Promising Early Data

In December 2025, CellCentric presented Phase 2 dose optimization data for the 'InoPd regimen,' which combines inobrodib with Bristol Myers Squibb's (BMY) pomalidomide (Pomalyst) and dexamethasone, at the American Society of Hematology (ASH) meeting. The data showed an overall response rate (ORR) of 69% in a heavily pre-treated patient population with a median of five prior lines of therapy, most of whom were triple-refractory. Based on these promising results, the company initiated a pivotal Phase 2 trial, 'DOMMINO-1 (NCT07096778),' in March 2026, enrolling 100 patients in the United States and the United Kingdom, to accelerate the approval process.

Potential for Synergistic Effects with Existing Standard Treatments and Competing Pipelines

The multiple myeloma market is currently led by existing standard treatments such as pomalidomide, as well as bispecific antibody therapies like Pfizer's (PFE) elrexfio and Johnson & Johnson's (JNJ) tecvayli. Inobrodib is being evaluated in combination with these existing therapies, as well as in monotherapy, to maximize immune response without increasing toxicity. The company aims to establish itself as a key component of combination therapy regimens by providing an effective treatment option for patients who have progressed after bispecific antibody therapy, thereby expanding beyond a niche market.

FDA Regulatory Benefits and Growing Commercialization Expectations

Inobrodib has already received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma in June 2023. These designations mitigate regulatory risks in new drug development and increase the potential for market exclusivity, thereby enhancing its commercial value. With this significant investment, the company is well-positioned to transition to commercialization after completing clinical trials. The success of the late-stage clinical trials will undoubtedly mark a turning point in the treatment of multiple myeloma.